SLC5A1 and Hyperglycemia: Canagliflozin is a moderate SGLT1 inhibitor drug [14] generating a decrease in hyperglycemia levels in patients with DM, and it has been reported that the inhibition of SGLT1 in the small intestine favors a decrease in intestinal glucose absorption [15].